Thomas Schluep
Nessuna posizione attualmente
Profilo
Dr. Thomas Schluep is Chief Scientific Officer at Calando Pharmaceuticals, Inc. and Vice President-Program Management at Arrowhead Research Corp.
Dr. Schluep was previously employed as Chief Scientific Officer by Insert Therapeutics, Inc., a Principal by Canji, Inc., and a Principal by Massachusetts Institute of Technology.
He received his graduate degree from the Swiss Federal Institute of Technology and a doctorate degree from the Swiss Federal Institute of Technology.
Precedenti posizioni note di Thomas Schluep
| Società | Posizione | Fine |
|---|---|---|
Insert Therapeutics, Inc.
 Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Direttore Tecnico/Scientifico/R&S | 08/09/2008 |
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Canji, Inc.
 Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Corporate Officer/Principal | - |
Calando Pharmaceuticals, Inc.
 Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Thomas Schluep
| Swiss Federal Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Insert Therapeutics, Inc.
Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Commercial Services |
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Health Technology |
Canji, Inc.
Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Health Services |
- Borsa valori
- Insiders
- Thomas Schluep
